- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Medco licenses new radiopharmaceutical
Drug developer Medco Research has acquired a new technetium-basedcardiac radiopharmaceutical, the Research Triangle Park, NC, companyannounced last week. Medco acquired the agent through a licensingdeal with the product's developer, Molecular Targeting
Drug developer Medco Research has acquired a new technetium-basedcardiac radiopharmaceutical, the Research Triangle Park, NC, companyannounced last week. Medco acquired the agent through a licensingdeal with the product's developer, Molecular Targeting Technologyof Malvern, PA. The drug, called technetium-99m Glucarate, isdesigned for the early diagnosis of acute myocardial infarctionand is in phase-I clinical trials.
Medco will have exclusive worldwide rights to develop, manufactureand market the agent. Molecular Targeting will retain rights inAsia, with the exception of Japan.
Another Medco cardiac imaging agent, ViaScint, has completedphase-III trials and the company is planning to file a new drugapplication shortly. ViaScint is designed to help predict whichpatients will have improvement in cardiac function following revascularization.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
